Aurobindo Pharma (AUROPHARMA) Stock Overview
A pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
AUROPHARMA Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,622.10 |
| 52 Week High | ₹1,682.40 |
| 52 Week Low | ₹1,016.10 |
| Beta | 0.022 |
| 1 Month Change | 4.64% |
| 3 Month Change | 7.30% |
| 1 Year Change | 49.70% |
| 3 Year Change | 89.10% |
| 5 Year Change | 138.16% |
| Change since IPO | 2,323.03% |
Recent News & Updates
Analysis Article • Aug 08
Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Investors in Aurobindo Pharma Limited ( NSE:AUROPHARMA ) had a good week, as its shares rose 4.9% to close at ₹1,658...
Narrative Update • Aug 04
AUROPHARMA: Fair Value Reset Balances Licensing Expansion And Execution Risks
Analysts have lifted their fair value estimate for Aurobindo Pharma from about ₹1,520 to roughly ₹1,571, citing adjusted assumptions for revenue growth, profit margins and future P/E as the key drivers of the higher target. Analyst Commentary Recent valuation work on Aurobindo Pharma reflects a mix of optimism on execution and caution around the assumptions that underpin the new fair value estimate.Recent updates
Analysis Article • Aug 08
Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Investors in Aurobindo Pharma Limited ( NSE:AUROPHARMA ) had a good week, as its shares rose 4.9% to close at ₹1,658...Narrative Update • Aug 04
AUROPHARMA: Fair Value Reset Balances Licensing Expansion And Execution Risks
Analysts have lifted their fair value estimate for Aurobindo Pharma from about ₹1,520 to roughly ₹1,571, citing adjusted assumptions for revenue growth, profit margins and future P/E as the key drivers of the higher target. Analyst Commentary Recent valuation work on Aurobindo Pharma reflects a mix of optimism on execution and caution around the assumptions that underpin the new fair value estimate.
Narrative Update • Jul 21
AUROPHARMA: Rich P E Will Expose Any Biologics Execution Setback
Analysts have raised their fair value estimate for Aurobindo Pharma, increasing the implied price target from ₹1,118.51 to ₹1,185.80 as they factor in slightly stronger revenue growth, marginally higher profit margins and a modestly richer future P/E assumption. Analyst Commentary Recent research on Aurobindo Pharma points to a more balanced stance from the Street, where a higher fair value estimate is paired with a clearer focus on execution risk, regulatory exposure and the quality of future growth.Narrative Update • Jul 07
AUROPHARMA: Margin Reset Buyback And New Approvals Will Shape Future Balance
Analysts have raised their price target fair value for Aurobindo Pharma from ₹1,379.96 to ₹1,519.97, citing updated assumptions that now factor in a shift from previously declining revenues to projected revenue growth, a lower profit margin profile, and a slightly higher future P/E multiple. Analyst Commentary Recent research commentary around Aurobindo Pharma gives investors a mixed but useful read on how the updated fair value ties back to expectations for execution, profitability, and growth assumptions.
Narrative Update • Jun 23
AUROPHARMA: Biologics Capacity And Pipeline Execution Will Support Future Upside
Analysts have lifted Aurobindo Pharma's fair value estimate from ₹1,640 to ₹1,785, linking the higher price target to updated assumptions that include a slightly higher discount rate, more moderate revenue growth and profit margin expectations, and a higher future P/E multiple. Analyst Commentary Analysts covering Aurobindo Pharma are framing the revised fair value estimate as part of a broader recalibration of expectations, with a stronger focus on how the company can execute on its growth plans while maintaining discipline on costs and capital allocation.Narrative Update • Jun 06
AUROPHARMA: Rich P E Assumptions Will Magnify Any Margin Execution Slip
The analyst fair value estimate for Aurobindo Pharma has been revised from ₹1,037.51 to ₹1,118.51, with analysts citing updated assumptions for revenue growth, profit margins, and future P/E as the key drivers behind the change. Analyst Commentary Analysts covering Aurobindo Pharma generally frame the revised fair value estimate in the context of execution on growth plans, the sustainability of margins, and how much investors are willing to pay on a P/E basis.Analysis Article • May 24
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,466
Shareholders might have noticed that Aurobindo Pharma Limited ( NSE:AUROPHARMA ) filed its full-year result this time...Narrative Update • May 05
AUROPHARMA: Margin Reliance On US Approvals Will Expose Execution Weakness
Analysts have nudged their price target for Aurobindo Pharma slightly higher to about ₹1,038 from roughly ₹1,034, citing updated assumptions that combine more cautious revenue growth with higher profit margin expectations and a modestly lower future P/E multiple. Analyst Commentary Recent research on Aurobindo Pharma sits in a cautious zone, even with the slightly higher price target.Narrative Update • Apr 21
AUROPHARMA: Margin Assumptions Buyback And USFDA Approvals Will Shape A Measured Outlook
Narrative update on Aurobindo Pharma The analyst fair value estimate for Aurobindo Pharma has moved slightly higher to about ₹1,380 from roughly ₹1,366, with analysts citing small adjustments to revenue expectations, a modestly higher profit margin assumption near 23.3%, and a slightly lower future P/E input as the key drivers of this change. Analyst Commentary Recent Street research on other global equities highlights how analysts are adjusting models, price targets, and ratings in response to changes in growth assumptions, cash flow, and perceived execution risks.Narrative Update • Apr 07
AUROPHARMA: Higher Margin Assumptions And Buybacks Will Shape A Balanced Outlook
Analysts have lifted their fair value estimate for Aurobindo Pharma to about ₹1,366 from roughly ₹1,293, citing model updates that reflect a lower discount rate, a higher projected profit margin of around 23%, and a slightly lower assumed future P/E multiple. Analyst Commentary Analysts looking at Aurobindo Pharma are focusing on how recent model tweaks, particularly around discount rates, profit assumptions, and valuation multiples, affect the risk and reward profile for shareholders.Narrative Update • Mar 23
AUROPHARMA: Lower P/E Expectations Will Challenge Execution On Margin Assumptions
Narrative Update on Aurobindo Pharma The analyst price target for Aurobindo Pharma has been adjusted slightly lower from about ₹1,046.76 to about ₹1,033.98 as analysts factor in updated assumptions for revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research on other companies shows a mix of optimism and caution, and the modest reduction in the average price target for Aurobindo Pharma to about ₹1,033.98 fits into that more measured tone.Narrative Update • Mar 09
AUROPHARMA: Margin Discipline And Biologics Expansion Will Support Future Upside
Analysts have kept their fair value estimate for Aurobindo Pharma steady at ₹1,640 per share, citing updated assumptions that reflect revised projections for revenue and profit margins along with a slightly lower future P/E multiple. Analyst Commentary Analysts covering Aurobindo Pharma are largely framing the current fair value as a function of execution on growth initiatives, disciplined margin management, and a more measured view on future valuation multiples.Narrative Update • Feb 23
AUROPHARMA: Margin Assumptions And Lower P/E Multiple Will Test Execution
Analysts have nudged their price target for Aurobindo Pharma slightly higher to ₹1,046.76 from ₹1,043.83, citing adjustments to profit margin assumptions and a lower forward P/E multiple in their updated models. Analyst Commentary Even with the modest upward tweak to the price target, some bearish analysts are still flagging risks that could cap upside for Aurobindo Pharma if execution or assumptions do not line up with reality.Analysis Article • Feb 12
Analysts Have Made A Financial Statement On Aurobindo Pharma Limited's (NSE:AUROPHARMA) Third-Quarter Report
Last week, you might have seen that Aurobindo Pharma Limited ( NSE:AUROPHARMA ) released its third-quarter result to...Narrative Update • Feb 09
AUROPHARMA: Richer Future P/E Assumptions Will Heighten Execution Risk
Analysts have raised their price target for Aurobindo Pharma from ₹949.46 to ₹1,043.83, reflecting updated models that incorporate slightly higher revenue growth, a small improvement in profit margin, a modestly lower discount rate, and a higher assumed future P/E multiple. Analyst Commentary While the higher price target for Aurobindo Pharma reflects updated assumptions on growth, margins, and valuation, not all market commentary is outright bullish.Analysis Article • Feb 03
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Jan 26
AUROPHARMA: Execution Risks On Timely Delivery Will Challenge Margin Resilience
Analysts have nudged their price target for Aurobindo Pharma slightly higher to ₹949.46 from ₹942.15, reflecting updated assumptions that pair somewhat lower revenue growth estimates with a modestly stronger profit margin outlook and a largely unchanged future P/E multiple. Analyst Commentary Recent Street research on other companies highlights how quickly sentiment can shift when expectations around growth, profitability, or execution become more uncertain.Narrative Update • Jan 11
AUROPHARMA: Execution Risks On Future Earnings Delivery Will Pressure Margin Optimism
Analysts have nudged their fair value estimate for Aurobindo Pharma slightly higher to ₹942.15 from ₹939.36, citing updated assumptions that combine a modest tweak to revenue growth with a marginally stronger profit margin outlook and a similar forward P/E expectation. Analyst Commentary Recent Street research around other companies highlights how quickly sentiment can shift when expectations on growth, execution, or timing come under pressure.Narrative Update • Dec 26
AUROPHARMA: Margin Optimism Will Face Pressure From Execution And Regulatory Risks
The analyst price target for Aurobindo Pharma has been raised from ₹863 to ₹939 as analysts update their models to reflect modestly higher margin expectations and a slightly richer future earnings multiple despite a marginal trim to long term revenue growth assumptions. Analyst Commentary While the recent price target revision for Aurobindo Pharma reflects greater confidence in margins and earnings quality, not all signals across the broader research landscape are uniformly positive for comparable growth and innovation driven names.Analysis Article • Dec 21
Aurobindo Pharma Limited (NSE:AUROPHARMA) Shares Could Be 27% Above Their Intrinsic Value Estimate
Key Insights Aurobindo Pharma's estimated fair value is ₹968 based on 2 Stage Free Cash Flow to Equity Aurobindo...Narrative Update • Dec 12
AUROPHARMA: Margin Expansion And Pipeline Execution Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Aurobindo Pharma from ₹1,724 to ₹1,640, reflecting a modestly higher discount rate and lower future P E multiple, even as they factor in stronger revenue growth and expanding profit margins. Analyst Commentary Bullish analysts acknowledge the trimmed fair value but continue to view Aurobindo Pharma as well positioned to compound earnings, supported by a healthier product mix, scale benefits, and operating leverage in key export markets.Analysis Article • Nov 29
Investors Don't See Light At End Of Aurobindo Pharma Limited's (NSE:AUROPHARMA) Tunnel
With a price-to-earnings (or "P/E") ratio of 20.8x Aurobindo Pharma Limited ( NSE:AUROPHARMA ) may be sending bullish...Analysis Article • Sep 26
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narrative Update • Sep 04
Biosimilars Expansion And EU Approvals Will Unlock Global Markets
Given that both the consensus revenue growth forecast and future P/E remained steady, there has been no material change in analyst sentiment, resulting in the consensus price target for Aurobindo Pharma remaining unchanged at ₹1293. What's in the News Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva Group for $5–5.5 billion from Advent International, which would be the largest-ever acquisition by an Indian pharma company; the acquisition would significantly boost Aurobindo’s footprint in the Eastern European market, especially in Czech Republic, Romania, and Slovakia (Key Developments).Analysis Article • Sep 04
We Discuss Whether Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Is Due For A Pay Rise
Key Insights Aurobindo Pharma to hold its Annual General Meeting on 10th of September Salary of ₹28.2m is part of CEO...Analysis Article • Aug 27
Estimating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Key Insights The projected fair value for Aurobindo Pharma is ₹898 based on 2 Stage Free Cash Flow to Equity Current...
New Narrative • Jan 05
Penicillin G Ramp-Up And Biosimilar Breakthroughs To Propel Revenue Growth And Boost Net Margins
Strategic focus on new product launches and U.S. pricing stability can drive revenue growth while improving EBITDA margins.Shareholder Returns
| AUROPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.2% | 0.8% | -0.1% |
| 1Y | 49.7% | 16.9% | 4.8% |
Return vs Industry: AUROPHARMA exceeded the Indian Pharmaceuticals industry which returned 16.9% over the past year.
Return vs Market: AUROPHARMA exceeded the Indian Market which returned 4.8% over the past year.
Price Volatility
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AUROPHARMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 29,209 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products.
Aurobindo Pharma Limited Fundamentals Summary
| AUROPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹933.32b |
| Earnings (TTM) | ₹37.13b |
| Revenue (TTM) | ₹349.35b |
25.1x
P/E Ratio2.7x
P/S RatioIs AUROPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUROPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹349.35b |
| Cost of Revenue | ₹143.75b |
| Gross Profit | ₹205.60b |
| Other Expenses | ₹168.47b |
| Earnings | ₹37.13b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 14, 2026
| Earnings per share (EPS) | 64.52 |
| Gross Margin | 58.85% |
| Net Profit Margin | 10.63% |
| Debt/Equity Ratio | 21.3% |
How did AUROPHARMA perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/14 16:47 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurobindo Pharma Limited is covered by 48 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Kamlesh Kotak | Asian Markets Securities Private Limited |